A morphology- and kinetics-based cascade for human neural cell high content screening
Related Experiment Video
Updated: Aug 8, 2026

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Gillian R Richards1, Alison J Smith, Frances Parry
1The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, UK. gillian_richards@merck.com
Abstract:
The prospect of manipulating endogenous neural stem cells to replace damaged tissue and correct functional deficits represents a novel mechanism for treating a variety of central nervous system disorders. Using human neural precursor cultures and a variety of assays for studying stem cell behavior we have screened two libraries of commercially available compounds using an endpoint high content screening assay. We then performed detailed follow-up mechanistic studies on confirmed hits using endpoint and kinetics assays to characterize and differentiate the mechanisms of action of these compounds. The screening cascade employed successfully identified a number of active compounds with differing mechanisms of action. This approach shows how hits from a phenotypic screen can be prioritized and characterized by high content screening to identify potentially novel mechanisms and druggable targets to take forward into more conventional high-throughput screening approaches.
More Related Videos
09:19High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
06:50Post-differentiation Replating of Human Pluripotent Stem Cell-derived Neurons for High-content Screening of Neuritogenesis and Synapse Maturation
Published on: August 28, 2019